Optimizing Treatment Decisions in Metastatic Castration-Resistant Prostate Cancer

December 5, 2019

Sponsored by:

Sponsored by:

 

Ongoing developments in diagnostic/predictive biomarkers and novel therapies are changing the landscape for the management of men with castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC). In particular, the number of FDA-approved androgen receptor (AR)-targeted therapies has increased and the indications for these agents are broadening so that they are being used earlier in the spectrum of prostate cancer.

This Urology Times® supplement presents highlights from a tele-roundtable of urologists and oncologists with extensive experience managing CRPC. Four experts, representing different practice settings, address common questions about patient evaluation and management, including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC.